Observational analysis found finerenone improves cardiac parameters in diabetic kidney disease, suggesting it may enhance heart function in affected patients.
Key Points
Treatment with finerenone resulted in stabilized cardiac parameters over six months in patients with DKD.
At baseline, 71% of patients had HFpEF or HFmrEF, indicating significant cardiac involvement in DKD.
Glomerular filtration rate declined slightly after four weeks, but side effects were minimal and well-managed.
Left atrial volume index showed significant decrease at four weeks and six months, indicating improved heart structure.